Please find the enclosure
SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
SMS Pharmaceuticals reported standalone revenue of Rs 88,687 lakhs for FY26, up 13.3% from Rs 78,275 lakhs in FY25. Net profit after tax grew 28.1% to Rs 8,761 lakhs from Rs 6,838 lakhs. On consolidated basis, PAT attributable to shareholders rose 47.5% to Rs 10,199 lakhs, boosted by associate VKT Pharma's profit contribution of Rs 1,399 lakhs. EPS improved to Rs 9.58 standalone and Rs 11.15 consolidated. The board recommended a dividend of Rs 0.40 per share (40%). Statutory auditors issued an unmodified (clean) opinion. The company raised Rs 4,762.50 lakhs by converting 50 million share warrants into equity shares.
The company delivered robust profit growth exceeding 25% with clean audit confirmation, which is positive for shareholders. The significant increase in consolidated PAT was driven by associate company performance, indicating good portfolio returns. Capital expansion through increased CWIP suggests ongoing investment in growth capacity.